Variations in pill appearance of antiepileptic drugs and the risk of nonadherence

JAMA Internal Medicine

Volumn 173, Issue 3, 2013, Pages 202-208

  Kesselheim, Aaron S ^a   Misono, Alexander S ^a   Shrank, William H ^a,c   Greene, Jeremy A ^a,b   Doherty, Michael ^a   Avorn, Jerry ^a   Choudhry, Niteesh K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c CENTERS FOR MEDICARE AND MEDICAID SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID; ZONISAMIDE;

ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PILL; PRESCRIPTION; PRIORITY JOURNAL; SEIZURE;

ADULT; ANTICONVULSANTS; CASE-CONTROL STUDIES; COLOR; DOSAGE FORMS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS;

EID: 84874074498     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/2013.jamainternmed.997     Document Type: Article

References (50)

1. Generic Pharmaceutical Association. Facts at a glance. http://gphaonline.org/about-gpha/about-generics/facts. Accessed October 4, 2012.
2. Harrison C. Patent watch: The patent cliff steepens. Nat Rev Drug Discov. 2011; 10(1):12-13.
3. Kesselheim AS, Fischer MA, Avorn J. Extensions of intellectual property rights and delayed adoption of generic drugs: Effects on Medicaid spending. Health Aff (Millwood). 2006;25(6):1637-1647.
4. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA. 2007; 298(1):61-69.
5. National Community Pharmacists Association. Take as directed: A prescription not followed. http://www.ncpanet.org. Accessed August 3, 2012.
6. World Health Organization. Adherence to long-term therapies: Evidence for action. http://www.who.int/chp/knowledge/publications/adherence-introduction. pdf. Accessed August 3, 2012.
7. Cutler DM, Everett W. Thinking outside the pillbox: Medication adherence as a priority for health care reform. N Engl J Med. 2010;362(17):1553-1555.
8. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brandname drugs used in cardiovascular disease: A systematic review and meta-analysis. JAMA. 2008;300(21):2514-2526.
9. Food and Drug Administration. Therapeutic equivalence of generic drugs: Letter to health practitioners. 1998 Jan 28. http://www.fda.gov/Drugs/ Development ApprovalProcess/HowDrugsareDevelopedandApproved/ ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm073182.htm. Accessed August 3, 2012.
10. Engelberg AB. The case for standardizing the appearance of bioequivalent medications. J Manag Care Pharm. 2011;17(4):321-323.
11. Stinson N. Trademarks and "look-alike" drugs. Indiana Law Rev. 1982;15(3):733-764.
12. Krieg M. Black Market Medicine. Englewood Cliffs, NJ: Prentice-Hall; 1967.
13. Greene JA, Kesselheim AS. Why do the same drugs look different? pills, trade dress, and public health. N Engl J Med. 2011;365(1):83-89.
14. Cutler C, Kesselheim A, Gabardi S, et al American Society of Blood and Marrow Transplantation. Generic immunosuppressants in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(3):285-290.
15. Greene JA. The substance of the brand. Lancet. 2011;378(9786):120-121.
16. Hakonsen H, Eilertsen M, Borge H, Toverud EL. Generic substitution: Additional challenge for adherence in hypertensive patients? Curr Med Res Opin. 2009; 25(10):2515-2521.
17. Shire US Inc v Barr Laboratories Inc. 329 F.3d 348 (3rd Circuit, 2003). http://law .justia.com/cases/federal/appellate-courts/F3/329/348/576516/. AccessedOctober 4, 2012.
18. Glaxo whistle-blower lawsuit: Bad medicine [transcript]. 60 minutes. CBS.December29,2010.http://www.cbsnews.com/stories/2010/12/29/60minutes/ main7195247-page2.shtml. Accessed August 3, 2012.
19. Kenagy JW, Stein GC. Naming, labeling, and packaging of pharmaceuticals. Am J Health Syst Pharm. 2001;58(21):2033-2041.
20. Ngoh LN. Health literacy: A barrier to pharmacist-patient communication and medication adherence. J Am Pharm Assoc (2003). 2009;49(5):e132-e146.
21. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among officebased physicians. Arch Intern Med. 2006;166(9):1021-1026.
22. Manjunath R, Davis KL, Candrilli SD, Ettinger AB. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav. 2009; 14(2):372-378.
23. Schmidt D. AED discontinuation may be dangerous for seizure-free patients.JNeural Transm. 2011;118(2):183-186.
24. Rubenstein S. Industry fights switch to generics for epilepsy. Wall Street Journal. July 13, 2007: A1.
25. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: Terminology and definitions. Value Health. 2008;11(1):44-47.
26. Kesselheim AS, Darby DL, Studdert DM, Glynn RJ, Levin RL, Avorn J. False Claims Act prosecution did not deter off-label drug use in the case of neurontin. Health Aff (Millwood). 2011;30(12):2318-2327.
27. Petersen ML, Wang Y, van der Laan MJ, Guzman D, Riley E, Bangsberg DR. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: A marginal structural model analysis. Clin Infect Dis. 2007;45(7):908-915.
28. Huang HY, Maguire MG, Miller ER III, Appel LJ. Impact of pill organizers and blister packs on adherence to pill taking in two vitamin supplementation trials. Am J Epidemiol. 2000;152(8):780-787.
29. Miller FG, Colloca L, Kaptchuk TJ. The placebo effect: Illness and interpersonal healing. Perspect Biol Med. 2009;52(4):518-539.
30. Hro'bjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. 2010;(1):CD003974.
31. Colloca L, Miller FG. The nocebo effect and its relevance for clinical practice. Psychosom Med. 2011;73(7):598-603.
32. Fitzgerald CL, Jacobson MP. Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures. Ann Pharmacother. 2011;45(5):e27.
33. Duh MS, Paradis PE, Latrémouille-Viau D, et al. The risks and costs of multiplegeneric substitution of topiramate. Neurology. 2009;72(24):2122-2129.
34. Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW; American Academy of Neurology. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology. 2007;68(16):1249-1250.
35. Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: A systematic review and meta-analysis. Drugs. 2010;70(5):605-621.
36. Hawaii Revised Statutes. §328-92(3)(c). 2008.
37. Tennessee Code Annotated. §53-10-210. 2009.
38. Utah Code Annotated. §58-17b-605. 2008.
39. Commonwealth of Massachusetts An Act to protect patients from breakthrough seizures (H.585). January 19, 2011.
40. Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther. 2010;88(3): 347-353.
41. Devine ST, Weisbart E, Barron J, Behm A. Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs. Curr Med Res Opin. 2010; 26(2):455-463.
42. Sandburg B. FDA rejects generic tablets larger than brand citing safety and efficacy concerns. Pink Sheet. 2012;27(2):29-30.
43. Horn CR, Cochrane GM. Colour coding for bronchodilator inhalers. Lancet. 1986; 1(8473):165.
44. Fischer MA, Choudhry NK, Brill G, et al. Trouble getting started: Predictors of primary medication nonadherence. Am J Med. 2011;124(11):1081, e9-e22.
45. Shrank WH, Gleason PP, Canning C, et al. Can improved prescription medication labeling influence adherence to chronic medications? an evaluation of the Target pharmacy label. J Gen Intern Med. 2009;24(5):570-578.
46. Faught E, Duh MS, Weiner JR, Guérin A, Cunnington MC. Nonadherence to antiepileptic drugs and increased mortality: Findings from the RANSOM Study. Neurology. 2008;71(20):1572-1578.
47. Margolese HC, Wolf Y, Desmarais JE, Beauclair L. Loss of response after switching from brand name to generic formulations: Three cases and a discussion of key clinical considerations when switching. Int Clin Psychopharmacol. 2010; 25(3):180-182.
48. Davit BM, Nwakama PE, Buehler GJ, et al. Comparing generic and innovator drugs: A review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009;43(10):1583-1597.
49. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332-337.
50. Choudhry NK, Avorn J, Glynn RJ, et al Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088-2097.